CDSCO Mandates Fixed Drug Eruption Warnings for Aceclofenac and Ibuprofen

The Central Drugs Standard Control Organisation has directed all State Licensing Authorities to mandate the inclusion of Fixed Drug Eruption as an adverse drug reaction in package inserts and promotional literature. This regulatory update specifically targets commonly prescribed non-steroidal anti-inflammatory drugs aceclofenac and ibuprofen. The directive aims to enhance patient safety awareness regarding dermatological side effects associated with regular pain relief medications.

The safety directive was formulated following formal recommendations from the National Coordination Centre for Pharmacovigilance Programme of India alongside dedicated expert committees. These bodies reviewed adverse event reporting data to identify consistent dermatological patterns linked to the systemic use of NSAIDs. Incorporating these standardized warnings ensures that healthcare providers and consumers receive clear information regarding potential hypersensitivity reactions.

Pharmaceutical manufacturers and distributors must update their product labeling and informational literature to comply with the new CDSCO guidelines. State regulators are tasked with overseeing the immediate enforcement of these labeling changes across all commercial batches. This measure underscores regulatory efforts to strengthen post-market surveillance and adverse drug reaction reporting nationwide.